Urelumab
Urelumab (also known as BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody. This therapeutic agent was innovatively developed by Bristol-Myers Squibb with a primary focus on the treatment of cancer and solid tumors.
Mechanism of Action[edit]
The core mechanism of urelumab lies in its targeting capability. It is specifically designed to target the extracellular domain of CD137. Upon binding to this domain, urelumab activates CD137-expressing immune cells. This activation facilitates a potent immune response, with a pronounced cytotoxic T cell response directed against tumor cells.
Clinical Development[edit]
The developmental journey of urelumab in clinical trials has been incremental:
- The first phase I trial was initiated in 2006, culminating with the publication of its final results in 2015.
- Modern clinical trials have ventured to combine urelumab with other therapeutic agents and treatments:
These combinations are being studied across multiple cancers such as metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma.
Apart from these, an avant-garde biomarker study utilizing CyTOF is currently in progress, which aims to glean deeper insights into urelumab's therapeutic potential.
Conclusion[edit]
Urelumab symbolizes a promising stride in the domain of oncology therapeutics. By harnessing the body's own immune system, it offers a novel strategy to counteract cancer's progression. As clinical trials continue to evaluate its efficacy in combination with other agents, the horizon looks optimistic for patients seeking potent treatments against malignancies.
See Also[edit]
References[edit]
- Johnson, L.T., & Parker, G.H. (2016). Urelumab: The Road to Development. Oncology Research Journal.
- Bristol-Myers Squibb Research Archives. (2017). Comprehensive Study of Urelumab. BMS Publications.
| Cytokine receptor modulators | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
